atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with SchizophreniaGlobeNewsWire • 12/14/21
atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology IndexGlobeNewsWire • 12/13/21
CB Therapeutics and atai Life Sciences launch TryptageniX to sustainably supply and develop clinically relevant compounds to tackle the growing mental health crisisGlobeNewsWire • 12/09/21
atai Life Sciences launches TryptageniX to further expand atai's robust intellectual property portfolio and strengthen atai's supply chainGlobeNewsWire • 12/09/21
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass PathwaysBenzinga • 11/29/21
Atai Life Sciences N.V. (ATAI) CEO Florian Brand on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/15/21
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate UpdateGlobeNewsWire • 11/15/21
atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business UpdateGlobeNewsWire • 11/08/21
This Psychedelics Stock Was Up More Than 20% Last Week, Outperforming Tesla, Nvidia and GameStopBenzinga • 11/02/21
atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social ChangeGlobeNewsWire • 10/19/21
What Is Precision Psychiatry? Biotech Company Leverages New Approach To Mental Health DisordersBenzinga • 10/11/21
atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx's Graduation to Toronto Stock Exchange After Positive Early Feasibility Study DataGlobeNewsWire • 09/15/21
Can Ketamine For Depression Be Improved? New Study Will Looks Into Ketamine Analog ArketamineBenzinga • 09/14/21
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depressionGlobeNewsWire • 09/14/21
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depressionGlobeNewsWire • 09/09/21
Atai Life Sciences N.V. (ATAI) CEO Florian Brand on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/16/21
atai Life Sciences Reports Second Quarter 2021 Financial Results and Business UpdateGlobeNewsWire • 08/16/21
atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health ConditionsGlobeNewsWire • 08/12/21